RU2020131372A - ИНГИБИТОРЫ микроРНК 22 - Google Patents
ИНГИБИТОРЫ микроРНК 22 Download PDFInfo
- Publication number
- RU2020131372A RU2020131372A RU2020131372A RU2020131372A RU2020131372A RU 2020131372 A RU2020131372 A RU 2020131372A RU 2020131372 A RU2020131372 A RU 2020131372A RU 2020131372 A RU2020131372 A RU 2020131372A RU 2020131372 A RU2020131372 A RU 2020131372A
- Authority
- RU
- Russia
- Prior art keywords
- nucleic acid
- seq
- composition according
- acid contains
- modifications
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862642934P | 2018-03-14 | 2018-03-14 | |
| US62/642,934 | 2018-03-14 | ||
| PCT/US2019/022351 WO2019178411A1 (en) | 2018-03-14 | 2019-03-14 | Inhibitors of micro-rna 22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2020131372A true RU2020131372A (ru) | 2022-04-14 |
Family
ID=67908026
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020131372A RU2020131372A (ru) | 2018-03-14 | 2019-03-14 | ИНГИБИТОРЫ микроРНК 22 |
| RU2020132725A RU2020132725A (ru) | 2018-03-14 | 2019-03-14 | Микро-рнк и ожирение |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020132725A RU2020132725A (ru) | 2018-03-14 | 2019-03-14 | Микро-рнк и ожирение |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11753639B2 (enExample) |
| EP (2) | EP3765619B1 (enExample) |
| JP (2) | JP7318166B2 (enExample) |
| KR (2) | KR20200132920A (enExample) |
| CN (2) | CN111918968B (enExample) |
| AU (2) | AU2019234917B2 (enExample) |
| BR (2) | BR112020018705A2 (enExample) |
| CA (2) | CA3093844A1 (enExample) |
| ES (1) | ES3001019T3 (enExample) |
| RU (2) | RU2020131372A (enExample) |
| SG (2) | SG11202008925VA (enExample) |
| WO (2) | WO2019178411A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111918968B (zh) | 2018-03-14 | 2023-11-24 | 贝斯以色列女执事医疗中心 | Micro-RNA 22的抑制剂 |
| CN110609142A (zh) * | 2019-10-09 | 2019-12-24 | 广州医科大学附属第二医院 | 一种检测外周血fto蛋白与自身调控元件结合能力的方法与应用 |
| CN115029347B (zh) * | 2022-05-11 | 2024-02-20 | 珠海中科先进技术研究院有限公司 | 识别和调控肝肾细胞纤维化的分子监测序列、重组质粒、抑制病毒 |
| CN116082447A (zh) * | 2022-09-09 | 2023-05-09 | 湖南大学 | 一种多肽及其制备方法 |
| CN117304258B (zh) * | 2022-09-09 | 2024-09-24 | 湖南大学 | 一种多肽的用途 |
| EP4353823A1 (en) * | 2022-10-12 | 2024-04-17 | Resalis Therapeutics S.r.l. | Inhibitors of micro-rna 22 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5981505A (en) | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
| US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
| US5840710A (en) | 1994-12-09 | 1998-11-24 | Genzyme Corporation | Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules |
| US6217900B1 (en) | 1997-04-30 | 2001-04-17 | American Home Products Corporation | Vesicular complexes and methods of making and using the same |
| WO1999001579A1 (en) | 1997-07-01 | 1999-01-14 | Isis Pharmaceuticals, Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
| SK17432000A3 (sk) | 1998-05-26 | 2001-07-10 | Icn Pharmaceuticals, Inc. | Zlúčenina, ktorá zahŕňa nukleozid s 2',4'-mostíkom a oligonukleotid z nej odvodený |
| US6838283B2 (en) | 1998-09-29 | 2005-01-04 | Isis Pharmaceuticals Inc. | Antisense modulation of survivin expression |
| US6693187B1 (en) | 2000-10-17 | 2004-02-17 | Lievre Cornu Llc | Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge |
| CA2487274A1 (en) | 2002-05-06 | 2003-11-13 | Nucleonics Inc. | Spermine chemically linked to lipids and cell-specific targeting molecules as a transfection agent |
| ES2534300T3 (es) * | 2004-11-12 | 2015-04-21 | Asuragen, Inc. | Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN |
| US20070213292A1 (en) * | 2005-08-10 | 2007-09-13 | The Rockefeller University | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
| CA2634046A1 (en) * | 2005-12-12 | 2007-06-21 | The University Of North Carolina At Chapel Hill | Micrornas that regulate muscle cell proliferation and differentiation |
| AU2013254923A1 (en) * | 2006-04-03 | 2013-11-28 | Santaris Pharma A/S | Pharmaceutical compositions comprising anti-miRNA antisense oligonucleotide |
| CA3042781C (en) * | 2006-04-03 | 2021-10-19 | Roche Innovation Center Copenhagen A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
| DK2205737T3 (da) * | 2007-10-04 | 2013-05-21 | Santaris Pharma As | Mikromirer |
| EP2419537B1 (en) * | 2009-04-13 | 2014-01-29 | Somagenics, Inc. | Methods and compositions for detection of small rnas |
| MA33488B1 (fr) | 2009-06-08 | 2012-08-01 | Miragen Therapeutics | Motifs de modification chimique pour des inhibiteurs et mimétiques de miarn |
| TW201238973A (en) * | 2010-12-17 | 2012-10-01 | Sanofi Sa | MiRNAs in joint disease |
| AU2012242761A1 (en) | 2011-04-12 | 2013-10-31 | Beth Israel Deaconess Medical Center, Inc. | Micro-RNA inhibitors and their uses in disease |
| US20150031574A1 (en) * | 2012-02-23 | 2015-01-29 | Sumitomo Bakelite Co., Ltd. | Method for classification of test body fluid sample |
| US9034839B2 (en) | 2012-04-20 | 2015-05-19 | Aptamir Therapeutics, Inc. | miRNA modulators of thermogenesis |
| WO2013181613A1 (en) | 2012-05-31 | 2013-12-05 | Research Development Foundation | Mirna for the diagnosis and treatment of autoimmune and inflammatory disease |
| EP2864482A4 (en) * | 2012-06-21 | 2016-02-10 | Miragen Therapeutics Inc | OLIGONUCLEOTIDE INHIBITORS COMPRISING A BLOCKED NUCLEIC ACID PATTERN |
| US9822358B2 (en) | 2013-10-18 | 2017-11-21 | Beth Israel Deaconess Medical Center | Treatment of cancers with micro-RNA inhibitors |
| US10358643B2 (en) * | 2014-01-30 | 2019-07-23 | Hoffmann-La Roche, Inc. | Poly oligomer compound with biocleavable conjugates |
| US20180023081A1 (en) | 2015-02-04 | 2018-01-25 | Bristol-Myers Squibb Company | Lna oligonucleotides with alternating flanks |
| WO2016149358A1 (en) * | 2015-03-16 | 2016-09-22 | Duncan Ross | Method of treatment comprising membrane-enclosed vesicle |
| EP3449001B1 (en) * | 2016-04-29 | 2021-12-08 | Aptamir Therapeutics, Inc. | Inhibition of mir-22 mirna by apt-110 |
| CN107432933A (zh) * | 2017-07-13 | 2017-12-05 | 中南大学湘雅三医院 | miR‑22作为靶位点在制备膀胱癌的化疗增敏治疗药物中的应用 |
| WO2019053235A1 (en) * | 2017-09-15 | 2019-03-21 | Genfit | NON-INVASIVE DIAGNOSIS OF NON ALCOHOLIC LIVER DISEASES, NON ALCOHOLIC STHEATHEPATITIS AND / OR HEPATIC FIBROSIS |
| CN111918968B (zh) | 2018-03-14 | 2023-11-24 | 贝斯以色列女执事医疗中心 | Micro-RNA 22的抑制剂 |
| WO2019217907A1 (en) * | 2018-05-11 | 2019-11-14 | The Regents Of The University Of California | Methods and compositions for the treatment of hepatic and metabolic diseases |
-
2019
- 2019-03-14 CN CN201980018587.XA patent/CN111918968B/zh active Active
- 2019-03-14 RU RU2020131372A patent/RU2020131372A/ru unknown
- 2019-03-14 KR KR1020207029243A patent/KR20200132920A/ko not_active Withdrawn
- 2019-03-14 CA CA3093844A patent/CA3093844A1/en active Pending
- 2019-03-14 KR KR1020207029242A patent/KR20200131287A/ko not_active Withdrawn
- 2019-03-14 CN CN201980032204.4A patent/CN112119159B/zh active Active
- 2019-03-14 RU RU2020132725A patent/RU2020132725A/ru unknown
- 2019-03-14 AU AU2019234917A patent/AU2019234917B2/en active Active
- 2019-03-14 AU AU2019234916A patent/AU2019234916B2/en active Active
- 2019-03-14 EP EP19768368.3A patent/EP3765619B1/en active Active
- 2019-03-14 BR BR112020018705-4A patent/BR112020018705A2/pt not_active Application Discontinuation
- 2019-03-14 SG SG11202008925VA patent/SG11202008925VA/en unknown
- 2019-03-14 WO PCT/US2019/022351 patent/WO2019178411A1/en not_active Ceased
- 2019-03-14 ES ES19768368T patent/ES3001019T3/es active Active
- 2019-03-14 CA CA3093572A patent/CA3093572A1/en active Pending
- 2019-03-14 JP JP2020573079A patent/JP7318166B2/ja active Active
- 2019-03-14 BR BR112020018752-6A patent/BR112020018752A2/pt not_active Application Discontinuation
- 2019-03-14 EP EP19768285.9A patent/EP3765610A4/en active Pending
- 2019-03-14 SG SG11202008921YA patent/SG11202008921YA/en unknown
- 2019-03-14 US US16/979,777 patent/US11753639B2/en active Active
- 2019-03-14 WO PCT/US2019/022350 patent/WO2019178410A1/en not_active Ceased
- 2019-03-14 JP JP2020549635A patent/JP2021518841A/ja active Pending
- 2019-03-14 US US16/979,782 patent/US11499152B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pikaard et al. | A transcription fork model for pol IV and pol v–dependent RNA-directed DNA methylation | |
| JP2015510393A5 (enExample) | ||
| EP2270042A3 (en) | KDR peptides and vaccines comprising the same | |
| CL2021000549A1 (es) | Péptido asociado a tumor (tumap); ácido nucleico; vector de expresión; célula hospedadora recombinante que comprende el péptido; método para producir el péptido; composición farmaceutica; uso para preparar un medicamento útil para tratar el cáncer; kit farmacéutico (divisional de la solicitud no. 201900460) | |
| HRP20192314T1 (hr) | Pripravci faktora viii i postupci pripreme i njihove uporabe | |
| HK1249433A1 (zh) | 含有mk2抑制剂肽的组合物用於治疗非小细胞肺癌的用途 | |
| RU2017143580A (ru) | Улучшенные последовательности уриказы и способы лечения | |
| WO2020047467A3 (en) | Cardiac cell reprogramming with myocardin and ascl1 | |
| RU2022103641A (ru) | Искусственная модификация генома для регуляции экспрессии гена | |
| CN103804482B (zh) | 一种抗菌肽及其应用 | |
| AR059300A1 (es) | Peptidos inhibidores de la fusion de vih con propiedades biologicas mejoradas | |
| JP2021518159A5 (enExample) | ||
| IN2014DN09963A (enExample) | ||
| SA515360229B1 (ar) | مثبطات عامل التمايز والنمو 8 | |
| RU2018142174A (ru) | Контролируемая пищевым рационом экспрессия нуклеиновой кислоты, кодирующей нуклеазу cas9, и ее применения | |
| JP2015533791A5 (enExample) | ||
| JP2011521661A5 (enExample) | ||
| MX2019006803A (es) | Composicion farmaceutica para prevenir o tratar la hepatitis b. | |
| CO2022009983A2 (es) | Ácido nucleico antisentido que permite la omisión de exones | |
| MX348555B (es) | Agente preventivo o terapeutico contra la fibrosis. | |
| JP2016222601A5 (enExample) | ||
| Chijiwa et al. | Structural characteristics and evolution of a novel venom phospholipase A2 gene from Protobothrops flavoviridis | |
| MX2018005146A (es) | Composicion que contiene de manera estable molecula de acido nucleico de un solo filamento que suprime la expresion de gen tgf-b1. | |
| WO2020093055A3 (en) | Peptide libraries with non-canonical amino acids | |
| JP2016516756A5 (enExample) |